Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

1 year ago

MENLO PARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on…

Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

1 year ago

Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR…

Singular Genomics to Present at Cowen’s 43rd Annual Health Care Conference

1 year ago

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing…

Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

1 year ago

Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6 million Cancer Prevention & Research…

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

1 year ago

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK)…

Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

1 year ago

MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products…

Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency

1 year ago

Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid AbsorptionREDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) --…

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

1 year ago

– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with…

Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress

1 year ago

Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s…

Risk From Pharma Reps Using Unapproved Content and Messaging in the Field Persists, but a Focus on Training Could Be the Answer

1 year ago

Study Reveals 50% of respondents in leadership roles catch incidents of field reps using unapproved content, but a continuous learning…